Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 11/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344557 | 0.87 | GRM2 (0.41) | PTPN1GRM2PIM1TGFBR1FAAH | |
| SCHEMBL3342031 | 0.76 | TGFBR1 (0.44) | GRM2TGFBR1LMNA | |
| SCHEMBL8007815 | 0.75 | NCK1 (0.55) | PTPN1GRM2PIM1 | |
| SCHEMBL5623414 | 0.73 | GRM2 (0.56) | PTPN1GRM2PIM1FAAH | |
| SCHEMBL15516376 | 0.71 | PIM1 (0.41) | PTPN1GRM2PIM1FAAHLMNA | |
| SCHEMBL3343307 | 0.71 | PTPN1 (0.38) | PTPN1GRM2PIM1FAAHLMNA | |
| SCHEMBL12505386 | 0.71 | NNMT (0.41) | PTPN1GRM2PIM1FAAHNNMT | |
| SCHEMBL3343146 | 0.69 | GRM2 (0.41) | PTPN1GRM2PIM1TGFBR1NNMT | |
| SCHEMBL18077323 | 0.69 | SCN7A (0.46) | PTPN1PIM1LRRK2 | |
| SCHEMBL4473874 | 0.68 | PIM1 (0.41) | PTPN1GRM2PIM1TGFBR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | PTPN1 1428/4885GRM2 496/4885PIM1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.